THE COMMERCIAL development of a new drug product, especially one intended for the treatment of a psychiatric condition, is a costly, time-consuming, resource-demanding, and financially risky undertaking. Only a small fraction of "potentially promising" new drug candidates ever make it into phase 1 clinical trials, and an even smaller proportion gain marketing approval. Moreover, among the candidates that eventually do reach the market, only a few can be deemed truly innovative, let alone major therapeutic advances.
Leber P. Not in Our Methods, but in Our Ignorance. Arch Gen Psychiatry. 2002;59(3):279-280. doi:10.1001/archpsyc.59.3.279